Alaunos Therapeutics Inc (TCRT)

[jondoeuk]

PACT Pharma plans to rapidly move to a product that has up to three TCRs, was (is?) adapting its screening system so that it can be used with any HLA allele and working on ways to improve its neoantigen- and TCR selection algorithms (learn from every patient).

[ClayTrader]

* * $ZIOP Video Chart 06-13-2019 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $ZIOP Video Chart 06-12-2019 * *

Link to Video - click here to watch the technical chart video

[jondoeuk]

From the PR: ''Positions Ziopharm to be first company to bring non-viral TCR-T into the clinic.''

No, that is PACT Pharma (NCT03970382). They have their own selection methods and are targeting non-shared (private) neoantigens.

[jondoeuk]

''These guys seem to be on the cusp of a cure for cancer.''

Sadly, that is not the case as there are a number of ways cancer cells can become immune to T-cells. Some of these are loss of target antigen(s), HLA, altered interferon or TNF-a signaling, and epigenetic. Some of the latter could be addressed with 5-azacitidine [1] or HDACi [2,3].

Refs:
1 https://www.nature.com/articles/bjc2011428
2 https://www.sciencedirect.com/science/article/pii/S0952791510002074
3 https://www.futuremedicine.com/doi/abs/10.2217/epi.15.16

[WalkingHome]

thanks, not much news on this, these guys seem to be on the cusp of a cure for cancer. Good stuff.

[whytestocks]

News: $ZIOP Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCI

– Positions Ziopharm to be first company to bring non-viral TCR-T into the clinic – – Company to host informational conference call June 12, 2019 at 8:30 am ET – BOSTON, June 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharmȁ...

Read the whole news https://marketwirenews.com/news-releases/ziopharm-oncology-announces-fda-clearance-of-ind-for-sleeping-beauty-tcr-t-cell-therapy-trial-at-nci-8336624.html

[jondoeuk]

Really?

[dirtydozen911]

I think it`s time to buy back in , if this drops under $4.....this stock has been very good to me the last few years,AND IT WILL BE AGAIN!!...$$$$$$$$$$$$$$ ziop $$$$$$$$$...GLTA

[Plegee]

Closed above 200 DMA on increased volume. Historically, not a strong indicator, but who knows if this time it will be different.

[Plegee]

Yes, any potential progress will come from Precigen, ZIOP is circling the drain; nothing but baseless promises and zero execution. Totally unqualified CEO (learn on the go), no staff or adequate financial resources, competition could care less about Sleeping Beauty. I violated my own biotech rule; never invest when the Chief Medical Officer is in a CEO role. Pathetic execution, nothing more than a "hope and a prayer" gamble now for b/e.

[blackcat]

I am patiently waiting for XON to spin off Precigen .........

[jondoeuk]

Precigen is going after solid tumours a number of different ways (see slide 15 from the link below).

Dr. Sabzevari has said: ''We have been working on attsite which is another non viral platform for delivery, and this is a unidirectional and has a much larger payload than sleeping beauty and would allow us to put multiple genes more than what we have in sleeping beauty and is highly sight specific which brings down the number of copies for insertion.''

https://jpmorgan.metameetings.net/events/healthcare19/sessions/23974-intrexon-corporation/presentation_slides

[jondoeuk]

The PR is damage control, and nothing but an act of desperation. The company needs to execute and deliver

[jondoeuk]

Precigen UltraCarT https://www.prnewswire.com/news-releases/precigen-announces-clearance-of-ind-to-initiate-phase-11b-study-for-first-in-class-prgn-3006-ultracar-t-therapy-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-aml-and-higher-risk-myelodysplastic-syndrome-mds-300770244.html

So the ZIOP POC trial still has an FDA hold placed on it, but Precigen's 2-day UltraCAR-T gets approval for a trial. Something doesn't add up here.

[jondoeuk]

Good luck with that......

The company has been under performing for years now. The TCR trial at the NCI is delayed yet again, the 3rd Gen CAR has an FDA hold still placed on it and Ad-RTS-hIL-12 is useless in rGBM like it was in melanoma and breast cancer. Meanwhile, the competition continues to move forward.

[ClayTrader]

* * $ZIOP Video Chart 11-21-18 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $ZIOP Video Chart 11-13-18 * *

Link to Video - click here to watch the technical chart video

[barnovage]

Long.

[ClayTrader]

* * $ZIOP Video Chart 08-07-18 * *

Link to Video - click here to watch the technical chart video

[Plegee]

Something going on, second trading day in a row with a strong uptrend. Recent CC was enthusiastic, but sorely lacking in substance once again. Critical trial now delayed to 2nd half of 2018 it appears, a contradiction already from a 1st half prediction made just this past December. Hopefully some partnership negotiations are getting serious. Competition catching up, our keys to the Kingdom looking more like automatic glass doors at your neighborhood mall.

[Plegee]

Even if this stock triples here from an unlikely partnership announcement, this has been a horrible investment. Kirk's convoluted arrangement with XON is keeping suitors away, they just don't want to deal with his twisted sense of business reality. He has been a star in the past, certainly not in this case. CEO should have business acumen, not a research background. Another Ed Lamphier Another cash raise needed this year, maybe this time they use Big Ed's Pawn shop, can't be any worse than the last one.

[gator16]

SAME AS ALWAYS !!! GOOD NEWS STOCK DROPS>>BAD NEWS STOCK DROPS !!

[buckiii2]

Feb 12th slide. http://www.ziopharm.com/pipeline/presentations-publications

[ClayTrader]

* * $ZIOP Video Chart 02-06-18 * *

Link to Video - click here to watch the technical chart video

[Regis999]

Which Billionaire Randall Kirk Biotech company is the most capital efficient based upon market cap? $HALO by a mile.


ZIOPHARM Oncology, Inc. $ZIOP) Capital Raised since inception $ 619.232 million Market Cap $ 607.5 million

For every dollar ZIOP has raised in capital it has resulted in $.98 of Market Cap

Randall Kirk and affiliates owns 7.4% of ZIOP times $ 607.5 Million ZIOP market cap or $ 44.9 Million

Halozyme Therapeutics, Inc. (HALO) Capital Raised since inception $ 718.553 million Market Cap $ 2.63845 Billion

For every dollar HALO has raised in capital it has resulted in $3.66 of Market Cap

Randall Kirk and affiliates owns 18.5% of HALO times $ 2.638 Billion HALO market cap or $ 488 Million---10 TIMES the ownership of ZIOP !!

Intrexon Corporation (XON) Capital Raised since inception $ 1.370 Billion Market Cap $ 1.509 Billion

For every dollar XON has raised in capital it has resulted in $1.10 of Market Cap

Randall Kirk and affiliates owns 52.1% of XON times $ 1.370 Billion XON market cap or $ 713.8 Million

Which Kirk Biotech is likely to be acquired first: $HALO--

$HALO Tweets following science https://twitter.com/fezziwig2008

[dirtydozen911]

getting ready to pounce on this again......jumped out mid sept, with a nice gain......a little bit lower and POW!! GLTA

[sandyraveon]

ZIOPHARM reportrs clinical data from Data from T-Cell Therapy Programs; shows continued survival benefit
5:25 AM ET 12/11/17 | Briefing.com
Co announced data supporting its non-viral approach to rapid manufacture of chimeric antigen receptor (CAR)-modified T cells to treat patients with cancers Two trials demonstrated that first-generation SB-modified CD19-specific CAR+ T cells appear to provide long-term cancer control when infused after hematopoietic stem-cell transplantation (HSCT) for patients with advanced CD19+ malignancies and could be detected years after administration in some recipients. All seven patients with advanced CD19+ non-Hodgkin's lymphoma (NHL) that received autologous T cells were alive at a median survival of 40 months since infusion, with progression-free survival (PFS) reported at 86% and overall survival (OS) at 100%. For 19 patients with advanced CD19+ acute lymphoblastic leukemia (ALL) and NHL infused with allogeneic T cells following HSCT, nine patients were alive with a median survival of 31 months. The PFS rate and OS rates are 32% and 49%, respectively. Of the subset of eight patients who received donor-derived T cells after haploidentical HSCT, PFS and OS rates are 50% and 63%, respectively. Persistence of circulating SB-modified CAR+ T cells was demonstrated at two years in an autologous and allogeneic patient and for four years in two autologous patients.

[buckiii2]

https://www.investorvillage.com/smbd.asp?mb=16353&mn=92761&pt=msg&mid=17751869

[TREND1]

ZIOP= Profit/Loss = US$ -165.3M

[buckiii2]

https://www.bizjournals.com/boston/news/2017/11/20/ziopharm-says-its-brain-cancer-drug-helped-trial.html

[Plegee]

KITE helping all CRT, gene efiting stocks and cykotine switches (BLCM). Many articles suggesting this is the first acquisition of many in this group space area. Hopefully this continues to lift this stock until it is finally our turn. PFE is my wild guess as a suitor or partner. Have no idea what is taking Merck so long to advance their studies.

[dirtydozen911]

mr kirk has his hand in the cookie jar again.....what else is new!!!

[dirtydozen911]

this month long downtrend has sucked!...need her to go back to her roller-coaster mode....maybe today starts a new trend..gltu

[now invest]

Nice move thus far today... up 9% !! Maybe getting ready for a run??

[dirtydozen911]

might take a nibble on this tomorrow if overall market conditions are favorable......?..?..?

[ddbl_our_buck]

..thanks for that, Im leaning that way myself..
Check ONV* for a similar chart pattern and similar perspective on value.
cheers..

[dirtydozen911]

made lots of money on this the last few years.......usually stop trading this above 6.50.......was getting ready to jump in again, but an insider sell and some other developments, have changed my mind........I think she`s gonna take a dive......if she gets down in the 4`s , might give her another look, and geta big chunk to sit on .....???????????

[Plegee]

Yes, underwhelmed. CVI has the reputation of aggressively working their stakes in various invested companies; apparently DNDN and CRMD have been in their stable in the past. Disappointed this is the best we could do for the ridiculous discount we offered. Things just don't feel right. Empty/over promises by Kirk and Cooper. Plan to be out if nothing material happens before the 90 day CVI lockout expiration. This thing will be optioned pinned to death.

[wiltonio]

CVI Investments, Inc. has filed a new 13G, reporting 6.8% ownership in $ZIOP - https://fintel.io/so/us/ziop

[Plegee]

Down 37 cents or 5% on no news today so the MM can play his little games and have all those 7 call options expire worthless. Blatant manipulation. Closed at $6.99 . . . . what a coincidence with those 2700+ 7 strike options open.

[Pennybuster]

ZIOPHARM Oncology, Inc. Nasdaq: $ZIOP 11-10-16 announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Thursday, November 17, 2016 at 4:40 p.m. GMT.
As previously announced, ZIOPHARM will host a conference call and webcast slide presentation Thursday, November 17, 2016, at 8:00 am ET to discuss information featured at the Society for Neuro-Oncology (SNO) Annual Meeting, including updated data from the Company’s Phase 1 study of Ad-RTS-hIL-12 + veledimex in high-grade glioma. The call can be accessed by dialing [phone] (U.S. and Canada) or [phone] (international). The passcode for the conference call is 11110235. To access the slides and live audio webcast, or the subsequent archived recording, visit the "Investors & Media" section of the ZIOPHARM website at www.ziopharm.com. A replay of the call will be available on the Company's website for two (2) weeks.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.


Contact:
Lori Ann Occhiogrosso
ZIOPHARM Oncology, Inc.
617-259-1987
[e-mail]

David Pitts
Argot Partners
212-600-1902
[e-mail]

[DrStockonomics]

ZIOP remains a buyout candidate. Lowering debt to make it more attractive to potential buyers. As for XON, it remains, in my opinion, a solid long term investment. Very volatile right now, but eventually will be a $100 stock in the not to distant future. They just have to many sectors they are involved in to fail.

[foster g]

Anyone know why the big rise today? XON good investment?

[Fibanotch]

let it pull back 30% ...then u'll get a good bang for ur buck!

[jondoeuk]

The webcast for the second quarter financial results will start at 4:30 PM ET on the 9th of this month http://ir.ziopharm.com/eventdetail.cfm?EventID=174958

[growacet]

Juno being sued, is Ziopharm next?

ZIOP JUNO and KITE mentioned:

http://www.avoidthebag.com/2016/07/juno-therapeutics-being-sued-is.html

[tpizzazz24]

Blood sucking ambulance chasers if you don't know that by now. Slumdog

[blackcat]

Those CA suits mean nothing. The law firms are pure ambulance chasers. It will likely be dismissed and companies carry insurance against them any way.

[stanace27]

Chart is wonderful